Clinical Trial: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06887348) titled 'A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3' on March 14.

Brief Summary: This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose of an RPx product under the interventional parent study. Patients will be rolled over into this LTFU study after completion of the Replimune-sponsored parent study (ie, either completion of the LTFU in the pare...